Corporate Finance

A Pittsburgh startup just secured major funding to fix a 60-year-old problem in EMS, potentially saving millions from secondary injuries during ambulance rides.

Silver Hill's massive fundraise isn't just a bet on oil and gas. It's a strategic play on energy security, AI's power thirst, and a slower-than-advertised transition.

Backed by Mark Cuban, Kind Designs uses 3D printing to create seawalls that double as marine habitats, merging climate resilience with ecological restoration.

With a fresh $4.2M, Proaction is replacing call centers with AI agents, targeting the inefficiencies of a massive, multi-billion dollar legacy industry.

With a $40M raise and a team of heavy-hitters, ORANGE JUICE is launching a permanent capital firm to acquire and hold businesses, backed by a Bitcoin treasury.

Defying a bear market, Pepeto's presale raises over $10M with promises of Layer 2 tech. But can its product-first approach overcome its anonymous leadership?

Backed by $180M, Celea Therapeutics is deploying a bold head-to-head superiority trial, aiming to prove its drug isn't just an alternative but a new standard.

HarbourVest's $4.75B fund signals a major trend: investors are bypassing old models for direct access to deals in AI and tech. What does this mean for you?

With a new name and $35M in fresh funding, Allotera Therapeutics is doubling down on a pivotal trial for Sofi-cel, a therapy aimed at solving a tough T-cell cancer.

As private equity faces a liquidity crunch, Patria Investments' oversubscribed secondary fund reveals a winning strategy: targeting smaller, overlooked deals.

Beyond software, a new breed of venture capital is funding America's industrial rebirth, pouring millions into AI, robotics, and the factories of the future.

Waste Pro's latest $150M bond deal isn't just about money; it's a look into the financial engine driving a private company's rapid southeastern expansion.

Amid a tough fundraising climate, Hamilton Lane's record fund close reveals a key strategy for 2026: the enduring power of the middle-market buyout.

Suominen's oversubscribed rights issue raises €28M, a strong investor endorsement for its ambitious 'Full Potential Program' aimed at a major overhaul.

Exact Imaging's U.S. expansion signals a major shift. With technology rivaling MRI, micro-ultrasound is poised to make precision diagnostics more accessible.

While many fintechs burn billions, Singapore’s Qashier hit profitability on a lean budget. We dissect how its unified platform cracked the fragmented SEA market.

With a new $155M fund, Larsen Jensen's firm is arming deep tech startups to win the next geopolitical race, blending military strategy with venture capital.

Almonty Industries' inclusion in the Russell 1000 is more than a stock market milestone. It validates a strategy built at the nexus of profit and geopolitics.

X Square Robot's $2.8B valuation, backed by China's four tech giants, signals a strategic shift from digital screens to intelligent, physical robots.

Biotech innovator Ernexa Therapeutics launches a new CEO platform, betting that open communication can help it solve cell therapy's biggest challenge: cost.